TECX (Tectonic Therapeutic) Treasury Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Tectonic Therapeutic's treasury stock for the quarter that ended in Dec. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Tectonic Therapeutic Treasury Stock Historical Data

The historical data trend for Tectonic Therapeutic's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Treasury Stock Chart

Tectonic Therapeutic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Treasury Stock

Tectonic Therapeutic Quarterly Data
	Dec21	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Treasury Stock	Get a 7-Day Free Trial			-	-	-	-	-

Tectonic Therapeutic Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Tectonic Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472

Website

https://www.tectonictx.com

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.